Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE plus microwave ablation versus TACE plus targeted drug in hepatocellular carcinoma with portal vein tumor thrombosis
ChiCTR2000037529Phase 4Not yet recruiting
- Sponsor
- Beijing Ditan Hospital
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sorafenib and lenvatinib in hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) (2 arms), sponsored by Beijing Ditan Hospital. Primary endpoint: Overall survival. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
sorafeniblenvatinib
03
Conditions
hepatocellular carcinoma (HCC)portal vein tumor thrombosis (PVTT)
Beyond the preview
Go deeper on ChiCTR2000037529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037529.